Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -$75.56M, compared with -$67.04M a year earlier. Trailing-twelve-month income before tax was -$309.11M.

Context

  • Income before tax amounted to 17253.3% of revenue in FY2025, up 15004.6 pp from a year earlier.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$75.56M or moves back toward the trailing-twelve-month quarterly average of -$77.28M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$75.56M-2.8% QoQ
Last fiscal yearDec 2025
-$258.8M-63.9% YoY
LTMSep 2026
-$309.11M-37.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.7%——
1 year-63.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(258.8M) USD
Year-over-year change
-63.9%

Income Before Tax vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 income before tax of -$309.11M is the 9th highest of the 10 companies compared; the peer median is -$68.17M.
  • Its year-over-year change of -37.7% is the 8th highest of 9, against a peer median of -6.6%.
  • Income before tax amounts to 275986.6% of revenue for CLDX, versus a peer median of 50.5%.
CLDX Competitors Peer median
Income Before Tax for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$308.21M +226.3%—43.9%
AGENAgenus Inc.LTM Mar 2026$62.49M +132.0%—50.5%
CGENCompugen Ltd.LTM Mar 2026$34.88M +463.6%—48.0%
ADAGAdagene Inc.LTM Jun 2024-$32.47M ——3980.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$68.17M -23.5%——
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M -29.5%—45.2%
XNCRXencor, Inc.LTM Jun 2026-$160.85M +10.3%—153.2%
IMNMImmunome, Inc.LTM Sep 2026-$282.65M -26.9%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M -37.7%—275986.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M -47.7%—386.3%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) -$68.17M-6.6%—50.5%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.